Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Study design

JS Julia Stowe
NA Nick Andrews
FK Freja Kirsebom
MR Mary Ramsay
JB Jamie Lopez Bernal
request Request a Protocol
ask Ask a question
Favorite

A test-negative case–control design was used to estimate vaccine effectiveness in those aged 18 years and over against hospitalisation following a PCR test for SARS-CoV-2, as described previously22–25. Cases were those testing positive and controls those testing negative by PCR. Effectiveness was assessed using a variety of hospitalisation endpoints designed to differentiate between hospitalisations likely to be because of COVID-19 and those that may be hospitalisation with COVID-19 but potentially due to another cause. Effectiveness against Omicron and Delta was assessed using periods in which these variants were circulating and using the information on sequencing, genotyping and PCR s-gene target.

Copyright and License information: Crown ©2022
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A